New York State Common Retirement Fund Purchases 37,388 Shares of Illumina, Inc. (NASDAQ:ILMN)

New York State Common Retirement Fund boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 36.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 138,993 shares of the life sciences company's stock after acquiring an additional 37,388 shares during the period. New York State Common Retirement Fund owned approximately 0.09% of Illumina worth $11,028,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of ILMN. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Illumina by 4.1% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,580 shares of the life sciences company's stock worth $2,082,000 after purchasing an additional 614 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Illumina by 10.4% in the 4th quarter. Signaturefd LLC now owns 1,880 shares of the life sciences company's stock valued at $251,000 after purchasing an additional 177 shares during the last quarter. Generali Asset Management SPA SGR acquired a new stake in shares of Illumina during the fourth quarter worth $924,000. Xponance Inc. raised its stake in Illumina by 6.2% during the fourth quarter. Xponance Inc. now owns 26,498 shares of the life sciences company's stock worth $3,541,000 after buying an additional 1,556 shares during the last quarter. Finally, Vinva Investment Management Ltd lifted its holdings in Illumina by 17.2% in the fourth quarter. Vinva Investment Management Ltd now owns 7,735 shares of the life sciences company's stock valued at $1,033,000 after buying an additional 1,135 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price for the company. in a research report on Friday, July 11th. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and reduced their target price for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Canaccord Genuity Group increased their price target on shares of Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Piper Sandler dropped their price target on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina presently has an average rating of "Hold" and an average target price of $125.11.

Insider Activity

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the firm's stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 2.60% of the company's stock.

Illumina Stock Performance

Illumina stock traded down $1.79 during trading hours on Friday, hitting $96.14. The stock had a trading volume of 1,888,348 shares, compared to its average volume of 2,159,170. The company has a 50-day moving average of $89.22 and a two-hundred day moving average of $95.19. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a market cap of $15.22 billion, a PE ratio of -15.84, a price-to-earnings-growth ratio of 1.88 and a beta of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. Illumina's revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.98 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.